Clinical Trial Detail

NCT ID NCT04074967
Title Study of ARRY-614 Plus Either Nivolumab or Ipilimumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jason J. Luke, MD
Indications

Advanced Solid Tumor

melanoma

renal cell carcinoma

Therapies

Ipilimumab + Pexmetinib

Nivolumab + Pexmetinib

Age Groups: adult senior

No variant requirements are available.